DK0556292T3 - Hepatitis C virus asialoglycoproteiner - Google Patents

Hepatitis C virus asialoglycoproteiner

Info

Publication number
DK0556292T3
DK0556292T3 DK92900091T DK92900091T DK0556292T3 DK 0556292 T3 DK0556292 T3 DK 0556292T3 DK 92900091 T DK92900091 T DK 92900091T DK 92900091 T DK92900091 T DK 92900091T DK 0556292 T3 DK0556292 T3 DK 0556292T3
Authority
DK
Denmark
Prior art keywords
virus
proteins
hepatitis
hcv
recombinant
Prior art date
Application number
DK92900091T
Other languages
English (en)
Other versions
DK0556292T4 (da
Inventor
Frank Marcus
Robert O Ralston
Kent B Thudium
Barbara A Gervase
John A Hall
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27417050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0556292(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DK0556292T3 publication Critical patent/DK0556292T3/da
Publication of DK0556292T4 publication Critical patent/DK0556292T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK92900091T 1990-11-08 1991-11-07 Hepatitis C virus asialoglycoproteiner DK0556292T4 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61141990A 1990-11-08 1990-11-08
US61196590A 1990-11-08 1990-11-08
US75888091A 1991-09-13 1991-09-13
PCT/US1991/008272 WO1992008734A1 (en) 1990-11-08 1991-11-07 Hepatitis c virus asialoglycoproteins

Publications (2)

Publication Number Publication Date
DK0556292T3 true DK0556292T3 (da) 2000-04-17
DK0556292T4 DK0556292T4 (da) 2006-12-27

Family

ID=27417050

Family Applications (2)

Application Number Title Priority Date Filing Date
DK97120661T DK0842947T4 (da) 1990-11-08 1991-11-07 Hepatitis C-virus-asialoglycoproteiner
DK92900091T DK0556292T4 (da) 1990-11-08 1991-11-07 Hepatitis C virus asialoglycoproteiner

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK97120661T DK0842947T4 (da) 1990-11-08 1991-11-07 Hepatitis C-virus-asialoglycoproteiner

Country Status (17)

Country Link
EP (2) EP0556292B2 (da)
JP (8) JPH06504431A (da)
AT (1) ATE188220T1 (da)
AU (1) AU668078B2 (da)
CA (2) CA2095521C (da)
CZ (1) CZ289006B6 (da)
DE (1) DE69131882T3 (da)
DK (2) DK0842947T4 (da)
ES (1) ES2139591T5 (da)
FI (1) FI107803B (da)
GR (1) GR3032771T3 (da)
HU (2) HU227498B1 (da)
NO (2) NO304380B1 (da)
PT (2) PT99466B (da)
RO (1) RO115446B1 (da)
SK (3) SK285624B6 (da)
WO (1) WO1992008734A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274148B1 (en) 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
JP3158177B2 (ja) * 1991-10-08 2001-04-23 国立感染症研究所長 Ｃ型肝炎診断薬
CA2129733C (en) * 1992-01-31 2006-10-31 James M. Casey Mammalian expression systems for hcv proteins
UA39944C2 (uk) * 1992-07-07 2001-07-16 Чірон Корпорейшн Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
CA2162557C (en) 1993-05-12 2004-09-28 Amy J. Weiner Conserved motif of hepatitis c virus e2/ns1 region
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
ES2244965T3 (es) 1994-07-29 2005-12-16 Chiron Corporation Complejos e1/e2 secretados de virus de la hepatitis c obtenidos de polipeptidos e1 y e2 truncados en c-terminal.
EP1211315A1 (en) 1994-07-29 2002-06-05 Innogenetics N.V. Recombinant vectors for producing HCV envelope proteins
PT773957E (pt) * 1994-07-29 2005-11-30 Chiron Corp Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos
IT1271593B (it) * 1994-11-30 1997-06-04 Sanitaria Scaligera Spa Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
FR2744725B1 (fr) * 1996-02-09 1998-04-30 Pasteur Institut Anticorps specifiques des complexes formes par les glycoproteines e1 et e2 du virus de l'hepatite c, procedes de determination de la presence, et d'isolement de ces complexes
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
KR100209095B1 (ko) 1996-06-28 1999-07-15 성재갑 C형 간염 바이러스의 프로테아제의 활성을 측정할 수 있는 c형 간염 대체 바이러스, 그 재조합 유전자 및 그 용도
DE69739268D1 (de) 1996-11-08 2009-04-02 Us Gov Health & Human Serv Herstellung und reinigung von hepatitis c virus-ähnlichen partikeln
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
ATE437951T1 (de) 1997-05-06 2009-08-15 Novartis Vaccines & Diagnostic Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
EP0947525A1 (en) 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
EP1311289B1 (en) 2000-08-17 2007-10-17 Tripep Ab Vaccines containing ribavirin
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US7022323B2 (en) 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
US20030232745A1 (en) * 2001-06-26 2003-12-18 Olson William C. Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection
EP1551960A4 (en) * 2002-08-16 2006-02-01 Univ Ohio PURIFICATION OF HEPATITIS VIRAL C TYPE PARTICLES
CA2618429A1 (en) 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US20090214593A1 (en) 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227011A (en) * 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
IL88599A0 (en) * 1987-12-10 1989-07-31 Cell Bio Group Ltd Glycoprotein cell growth modulating materials,their preparation and compositions containing them
HUT54896A (en) * 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
WO1991015771A1 (en) * 1990-04-04 1991-10-17 Chiron Corporation Combinations of hepatitis c virus (hcv) antigens for use in immunoassays for anti-hcv antibodies

Also Published As

Publication number Publication date
RO115446B1 (ro) 2000-02-28
SK44293A3 (en) 1993-08-11
EP0556292A4 (da) 1995-01-18
EP0842947B1 (en) 2004-04-21
NO304381B1 (no) 1998-12-07
HUT66063A (en) 1994-09-28
DE69131882T3 (de) 2007-05-24
JP2001286290A (ja) 2001-10-16
ES2139591T5 (es) 2007-08-01
NO304380B1 (no) 1998-12-07
JP2005187479A (ja) 2005-07-14
CA2095521A1 (en) 1992-05-09
DE69131882T2 (de) 2000-05-04
JPH06504431A (ja) 1994-05-26
JP2006219503A (ja) 2006-08-24
ES2139591T3 (es) 2000-02-16
GR3032771T3 (en) 2000-06-30
PT102022B (pt) 2000-12-29
AU9026791A (en) 1992-06-11
JP2003174875A (ja) 2003-06-24
CA2203443C (en) 2001-08-28
JPH1171395A (ja) 1999-03-16
JP4056306B2 (ja) 2008-03-05
WO1992008734A1 (en) 1992-05-29
EP0842947A2 (en) 1998-05-20
SK69097A3 (en) 1997-11-05
CA2203443A1 (en) 1992-05-09
FI932025A0 (fi) 1993-05-05
CZ82493A3 (en) 1994-04-13
HU227498B1 (en) 2011-07-28
CA2095521C (en) 2009-06-30
DK0842947T4 (da) 2009-06-08
NO931680D0 (no) 1993-05-07
EP0556292A1 (en) 1993-08-25
ATE188220T1 (de) 2000-01-15
SK286106B6 (sk) 2008-03-05
DE69131882D1 (en) 2000-02-03
DK0556292T4 (da) 2006-12-27
NO972213L (no) 1997-05-14
FI932025A (fi) 1993-06-07
PT99466B (pt) 1999-04-30
CZ289006B6 (cs) 2001-10-17
DK0842947T3 (da) 2004-07-26
JP3207155B2 (ja) 2001-09-10
EP0556292B1 (en) 1999-12-29
SK285623B6 (sk) 2007-05-03
NO931680L (no) 1993-06-28
JP2008031181A (ja) 2008-02-14
NO972213D0 (no) 1997-05-14
EP0842947B2 (en) 2009-03-18
PT99466A (pt) 1992-10-30
AU668078B2 (en) 1996-04-26
JP2003093081A (ja) 2003-04-02
HU9301336D0 (en) 1993-10-28
SK285624B6 (sk) 2007-05-03
EP0842947A3 (en) 2001-12-12
FI107803B (fi) 2001-10-15
PT102022A (pt) 1999-01-29
EP0556292B2 (en) 2006-11-29

Similar Documents

Publication Publication Date Title
DK0556292T3 (da) Hepatitis C virus asialoglycoproteiner
ATE229543T1 (de) Polypeptide des hepatitis c-virus (hiv)
DE69826661D1 (de) Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung
FI941199A0 (fi) Immunoreaktiiviset hepatiitti-C-viruksen polypeptidikoostumukset
DE69535018D1 (de) Papillomavirus vakzine
AU7234987A (en) Viral vector coding for a glycoprotein of the virus responsible for a.i.d.s., vaccine and antibody
FR2445338A1 (fr) Preparation de glycoproteine isolee d'enveloppes d'onco-rna virus et vaccins qui la contiennent
PT586076E (pt) Vacinas de adenovirus recombinantes
EP0216564A3 (en) Infectious recombinant virus, vaccines containing said virus for feline leukemia, and methods for the production thereof
EP1471073A3 (en) Hepatitis C virus asialoglycoproteins
FI971702A (fi) Hepatiitti-C-viruksen asialoglykoproteiinit
RU93043621A (ru) Способы получения гликопротеинов нсv, способ очистки, аналитический набор, способ выявления нсv, способ элиминации нсv, способ индукции иммунитета, гликопротеины, иммунореагенты
KR880003971A (ko) 재조합 바쿨로비루스 벡터로 부터 b형 간염비루스 항원의 발현
EP0888046A4 (en) METHOD FOR PROTEIN PRODUCTION BY MEANS OF A MITOCHONDRIAL TRANSLATION SYSTEM.
EP0385394A3 (en) Polyhedrin gene and genetic engineering thereof
EP0234862A3 (en) Expression of recombinant proteins in yeast
PT89041A (pt) Metodo de preparacao de diagnosticos e vacinas nanbv